Contract development and manufacturing organisation (revision 10)

A contract development and manufacturing organisation (CDMO) develops processes and manufactures material to the specification of a customer who sells it under their own name. The arrangement is ordinary across the pharmaceutical and fine-chemical industries and is not in itself remarkable.^[1]

Its consequence for anyone reading supplier documentation is that the organisation named on a catalogue is not necessarily the organisation that made the material. A brand may be a manufacturer, a distributor of its own contract-manufactured material, or a reseller of another's — and the documentation may not distinguish these.^[2]

The distinction matters for traceability rather than for quality as such. Contract-manufactured material with an intact record chain is fully traceable; the failure mode is a chain broken at the transfer, which is a records question. See Repackaging.^[1]

Services span process development, analytical method development, scale-up, manufacture and, in some cases, fill-finish. A customer may buy any subset: a fully developed process transferred in, or a molecule and a target specification with everything else contracted out.^[1]

For peptides the capability that matters is synthesis at scale with the associated preparative chromatography, since the purification step is the one that requires the largest capital equipment. A house able to synthesise but not to purify at scale is limited to crude supply, and the distinction shows up in the specification a customer can be offered rather than in any claim about capability.^[3]

Quality responsibility is defined by a quality agreement between the parties. In regulated manufacture the marketing authorisation holder remains responsible for the product regardless of who made it, and the agreement allocates the practical obligations.^[1]